Product Information
RENVELA 2.4 GM POWDER PACKET is a brand product labeled by Genzyme Corporation, priced at $17.1932 per EA under NDC 58468013102. Its NADAC has been published 390 times since Nov 28, 2013.
FDA first approved this application on Feb 18, 2009.
The High Outlier badge above means this manufacturer's average price in the SEVELAMER CARBONATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
2400 mg/1
Manufacturer
Genzyme CorporationNDC
58468013102
Classification
Brand
Dosage Form
POWDER, FOR SUSPENSION
Route
ORAL
Effective Date
5/21/2025
Active Ingredients
SEVELAMER CARBONATEApproval Type
New Drug (NDA)
FDA Application
NDA022318FDA Approved
2/18/2009
On Market Since
8/12/2009
Pharmacological Classes
Price Statistics
The NADAC for RENVELA 2.4 GM POWDER PACKET has been published 390 times since Nov 28, 2013, and over the history we have for it it has risen 84.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $17.1932 per EA |
|---|---|
| All-time high | $17.1990 (May 14, 2025) |
| All-time low | $9.3253 (Nov 28, 2013) |
| 52-week high | $17.1932 |
| 52-week low | $17.1932 |
| Median price | $16.3372 |
| Average price | $15.3863 |
| Largest weekly change | +9.9% (Nov 19, 2014) |
| Weeks tracked | 390 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
0.0%
1Y
0.0%
3Y
+5.6%
5Y
+5.6%
All
+84.4%
Last surveyed May 13, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 94% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Genzyme Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
SEVELAMER CARBONATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphate Binder class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RENVELA 2.4 GM POWDER PACKET?
The current National Average Drug Acquisition Cost (NADAC) for RENVELA 2.4 GM POWDER PACKET, manufactured by Genzyme Corporation, is $17.1932 per EA (NDC 58468013102), effective May 13, 2026.
How has the price of RENVELA 2.4 GM POWDER PACKET changed over time?
Over the history we have for it, the NADAC for RENVELA 2.4 GM POWDER PACKET has risen 84.4%. It has been tracked across 390 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for RENVELA 2.4 GM POWDER PACKET?
Since Nov 28, 2013, the NADAC for RENVELA 2.4 GM POWDER PACKET has ranged from a low of $9.3253 (Nov 28, 2013) to a high of $17.1990 (May 14, 2025), with a median of $16.3372 per EA.
Are there cheaper alternatives to RENVELA 2.4 GM POWDER PACKET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SEVELAMER 2.4 GM POWDER PACKET, is $1.0050 per EA — about 94% below RENVELA 2.4 GM POWDER PACKET.
Who manufactures RENVELA 2.4 GM POWDER PACKET?
RENVELA 2.4 GM POWDER PACKET (NDC 58468013102) is labeled by Genzyme Corporation, and CMS classifies it as a brand product.